Literature DB >> 22259120

A novel xeno-free and feeder-cell-free system for human pluripotent stem cell culture.

Qihui Wang1, Xiaoning Mou, Henghua Cao, Qingzhang Meng, Yanni Ma, Pengcheng Han, Junjie Jiang, Hao Zhang, Yue Ma.   

Abstract

While human induced pluripotent stem cells (hiPSCs) have promising applications in regenerative medicine, most of the hiPSC lines available today are not suitable for clinical applications due to contamination with nonhuman materials, such as sialic acid, and potential pathogens from animal-product-containing cell culture systems. Although several xeno-free cell culture systems have been established recently, their use of human fibroblasts as feeders reduces the clinical potential of hiPSCs due to batch-to-batch variation in the feeders and time-consuming preparation processes. In this study, we have developed a xeno-free and feeder-cell-free human embryonic stem cell (hESC)/hiPSC culture system using human plasma and human placenta extracts. The system maintains the self-renewing capacity and pluripotency of hESCs for more than 40 passages. Human iPSCs were also derived from human dermal fibroblasts using this culture system by overexpressing three transcription factors-Oct4, Sox2 and Nanog. The culture system developed here is inexpensive and suitable for large scale production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22259120      PMCID: PMC4875217          DOI: 10.1007/s13238-012-2002-0

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  24 in total

1.  Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers.

Authors:  Gillian M Beattie; Ana D Lopez; Nathan Bucay; Andrew Hinton; Meri T Firpo; Charles C King; Alberto Hayek
Journal:  Stem Cells       Date:  2005-04       Impact factor: 6.277

2.  Human embryonic stem cells express an immunogenic nonhuman sialic acid.

Authors:  Maria J Martin; Alysson Muotri; Fred Gage; Ajit Varki
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

3.  Derivation of human embryonic stem cells in defined conditions.

Authors:  Tenneille E Ludwig; Mark E Levenstein; Jeffrey M Jones; W Travis Berggren; Erika R Mitchen; Jennifer L Frane; Leann J Crandall; Christine A Daigh; Kevin R Conard; Marian S Piekarczyk; Rachel A Llanas; James A Thomson
Journal:  Nat Biotechnol       Date:  2006-01-01       Impact factor: 54.908

4.  Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells.

Authors:  Arefeh Ghodsizadeh; Adeleh Taei; Mehdi Totonchi; Ali Seifinejad; Hamid Gourabi; Behshad Pournasr; Nasser Aghdami; Reza Malekzadeh; Navid Almadani; Ghasem Hosseini Salekdeh; Hossein Baharvand
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

5.  Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette.

Authors:  Aba Somers; Jyh-Chang Jean; Cesar A Sommer; Amel Omari; Christopher C Ford; Jason A Mills; Lei Ying; Andreia Gianotti Sommer; Jenny M Jean; Brenden W Smith; Robert Lafyatis; Marie-France Demierre; Daniel J Weiss; Deborah L French; Paul Gadue; George J Murphy; Gustavo Mostoslavsky; Darrell N Kotton
Journal:  Stem Cells       Date:  2010-10       Impact factor: 6.277

6.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

7.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

8.  Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Authors:  Jacob Hanna; Marius Wernig; Styliani Markoulaki; Chiao-Wang Sun; Alexander Meissner; John P Cassady; Caroline Beard; Tobias Brambrink; Li-Chen Wu; Tim M Townes; Rudolf Jaenisch
Journal:  Science       Date:  2007-12-06       Impact factor: 47.728

9.  High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors.

Authors:  Yue Ma; Ali Ramezani; Rachel Lewis; Robert G Hawley; James A Thomson
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

10.  Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Authors:  Gabsang Lee; Eirini P Papapetrou; Hyesoo Kim; Stuart M Chambers; Mark J Tomishima; Christopher A Fasano; Yosif M Ganat; Jayanthi Menon; Fumiko Shimizu; Agnes Viale; Viviane Tabar; Michel Sadelain; Lorenz Studer
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

View more
  12 in total

1.  Human umbilical cord-derived MSC culture: the replacement of animal sera with human cord blood plasma.

Authors:  Yan Ding; Hua Yang; Jing Bo Feng; Ying Qiu; Dong Sheng Li; Yi Zeng
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-09-17       Impact factor: 2.416

Review 2.  A decade of transcription factor-mediated reprogramming to pluripotency.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Nat Rev Mol Cell Biol       Date:  2016-02-17       Impact factor: 94.444

3.  Efficient generation of functional epithelial and epidermal cells from human pluripotent stem cells under defined conditions.

Authors:  Joshua A Selekman; Nicholas J Grundl; Joshua M Kolz; Sean P Palecek
Journal:  Tissue Eng Part C Methods       Date:  2013-06-04       Impact factor: 3.056

Review 4.  Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale.

Authors:  Lynda S Wright; M Joseph Phillips; Isabel Pinilla; Derek Hei; David M Gamm
Journal:  Exp Eye Res       Date:  2014-02-16       Impact factor: 3.467

5.  Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome.

Authors:  Xiaoning Mou; Yuanbo Wu; Henghua Cao; Qingzhang Meng; Qihui Wang; Chengchao Sun; Shengshou Hu; Yue Ma; Hao Zhang
Journal:  Stem Cell Res Ther       Date:  2012-04-18       Impact factor: 6.832

6.  CCL2 enhances pluripotency of human induced pluripotent stem cells by activating hypoxia related genes.

Authors:  Yuki Hasegawa; Dave Tang; Naoko Takahashi; Yoshihide Hayashizaki; Alistair R R Forrest; Harukazu Suzuki
Journal:  Sci Rep       Date:  2014-06-24       Impact factor: 4.379

Review 7.  Human embryonic stem cell cultivation: historical perspective and evolution of xeno-free culture systems.

Authors:  Nina Desai; Pooja Rambhia; Arsela Gishto
Journal:  Reprod Biol Endocrinol       Date:  2015-02-22       Impact factor: 5.211

8.  Development of a xeno-free substrate for human embryonic stem cell growth.

Authors:  Hailin Zhu; Jinliang Yang; Yuquan Wei; Harry Huimin Chen
Journal:  Stem Cells Int       Date:  2015-03-16       Impact factor: 5.443

Review 9.  Defining synthetic surfaces for human pluripotent stem cell culture.

Authors:  Jack W Lambshead; Laurence Meagher; Carmel O'Brien; Andrew L Laslett
Journal:  Cell Regen (Lond)       Date:  2013-11-22

10.  Efficient reprogramming of naïve-like induced pluripotent stem cells from porcine adipose-derived stem cells with a feeder-independent and serum-free system.

Authors:  Yu Zhang; Chao Wei; Pengfei Zhang; Xia Li; Tong Liu; Yong Pu; Yunsheng Li; Zubing Cao; Hongguo Cao; Ya Liu; Xiaorong Zhang; Yunhai Zhang
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.